Video Experimental Relacionado

Updated: Sep 9, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.1K

Corrección de errores en "Exendin-4 atenúa la esteatosis hepática mediante la promoción de la vía

    BioMed research international
    |September 3, 2025
    PubMed
    Resumen

    Este estudio corrige el DOI de un artículo publicado anteriormente. El artículo corregido DOI es 10.1155/2022/4246086 para la citación y recuperación precisa.

    Más Videos Relacionados

    Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss07:03

    Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

    Published on: July 19, 2024

    1.0K
    A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium08:35

    A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

    Published on: May 18, 2021

    6.7K

    Videos de Conceptos Relacionados

    Delivery Pathways to the Lysosome01:36

    Delivery Pathways to the Lysosome

    Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
    Endocytosis
    In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
    7.0K
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
    416